ProKidney (NASDAQ:PROK) Director Brian Jg Pereira Sells 255,026 Shares of Stock

ProKidney Corp. (NASDAQ:PROK) Director Brian Jg Pereira sold 255,026 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $2.72, for a total value of $693,670.72. Following the completion of the transaction, the director owned 54,333 shares in the company, valued at $147,785.76. This represents a 82.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Brian Jg Pereira also recently made the following trade(s):

• On Thursday, November 13th, Brian Jg Pereira sold 502,136 shares of ProKidney stock. The shares were sold at an average price of $2.37, for a total value of $1,190,062.32.

ProKidney Trading Up 5.7%

Shares of NASDAQ PROK traded up $0.13 during midday trading on Friday, hitting $2.41. 1,335,185 shares of the company’s stock were exchanged, compared to its average volume of 4,689,348. The business’s fifty day moving average price is $2.81 and its two-hundred day moving average price is $2.12. The company has a market cap of $709.22 million, a price-to-earnings ratio of -4.38 and a beta of 1.75. ProKidney Corp. has a 12-month low of $0.46 and a 12-month high of $7.13.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.04 million. Equities analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PROK. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research report on Wednesday, October 8th. Zacks Research cut ProKidney from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.25.

Hedge Funds Weigh In On ProKidney

Several institutional investors and hedge funds have recently bought and sold shares of PROK. Zullo Investment Group Inc. purchased a new position in ProKidney in the 3rd quarter worth approximately $28,000. AQR Capital Management LLC grew its holdings in shares of ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after purchasing an additional 27,098 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in shares of ProKidney in the second quarter worth $36,000. Jefferies Financial Group Inc. purchased a new position in shares of ProKidney in the third quarter worth $158,000. Finally, Deutsche Bank AG raised its holdings in ProKidney by 49.4% during the 1st quarter. Deutsche Bank AG now owns 86,337 shares of the company’s stock valued at $76,000 after buying an additional 28,546 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.